Galapagos initiates the wind-down of cell therapy activities

Galapagos (GLPG) announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its board of directors has decided to initiate the wind-down of the company’s cell therapy activities. On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities following a review and sale process, including an exploration of potential divestment options. This decision was subject to the conclusion of consultations with works councils in Belgium and the Netherlands, which have now been completed. “We have now concluded the works council consultation process regarding our intention to wind down the Company’s cell therapy activities. We thank our dedicated colleagues for their commitment during this time of uncertainty as we now turn to executing the wind-down,” said Henry Gosebruch, CEO of Galapagos. “As we move forward, we will seek to continue the evolution of Galapagos through transformative business development.” The wind-down will impact approximately 365 employees across Europe, the U.S. and China, and will result in the closure of the sites in Leiden, Basel, Princeton, Pittsburgh and Shanghai.